Evidence map›Paper›PMID 42391634›Full record

ReviewIranian biomedical journal2026

Resveratrol in Combination Therapy: Mechanisms and Limitations of Resveratrol in Cancer, Regeneration, and Chronic Disease

Effat Noori, Ramazan Rezaei, Samira Valiyari, Mahmood Rekabgardan, Parvin Mohammadi, Fatemeh Soleymani, Elham Sharif, Zohreh Jafari, Delsuz Rezaee, Fatemeh Hajighasemi and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Effat NooriDepartment of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran.
Ramazan RezaeiDepartment of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran.
Samira ValiyariDepartment of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran.
Mahmood RekabgardanDepartment of Regenerative Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Parvin MohammadiRegenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Fatemeh SoleymaniDepartment of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran.
Elham SharifDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Zohreh JafariDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Delsuz RezaeeDepartment of Genetic and Molecular Medicine, School of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran.
Fatemeh HajighasemiDepartment of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran.
Forough ShamsDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol (RSV), a nonflavonoid polyphenol phytoalexin, has considerable therapeutic potential for managing chronic and acute diseases due to its anti-inflammatory, anti-cancer, antimicrobial, and antioxidant properties. It can help protect cells from free radical damage and modulate signaling pathways in the body to promote overall health. RSV can also facilitate the therapeutic effects of mesenchymal stem cells by increasing their self-renewal, survival, anti-aging effects, and lineage commitment. However, the natural form of RSV has limitations, such as poor intestinal absorption and low bioavailability. This review focuses on the potential of RSV to explore its effects and mechanisms of action in cancer, regenerative medicine, and chronic disease. It also discusses how RSV can protect normal tissue against genomic instability and presents findings from combination therapies involving RSV and nanoparticle-based agents. Overall, this review highlights the latest developments regarding RSV as a promising compound, emphasizing the potential to overcome its limitations.

Indexed as

NeoplasmsRegenerationResveratrolAnimalsAntioxidantsChronic DiseaseCombined Modality TherapyHumansStilbenesAntioxidantsResveratrolStilbenesNanoparticlesRegenerative medicineResveratrol

Identifiers

PMID42391634
PMCPMC13539227

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.